Evolent has more than 1,400 clinicians—including 300 physicians—focused on improving health outcomes for cancer, cardiovascular disease, musculoskeletal conditions and more. Watch to learn how our evidence-driven, patient-first model helps produce more informed treatment decisions.
Other content in this Stream
True peer-to-peer conversations will improve prior authorization
Dr. Matthew Walker writes in STAT about one big step to make peer conversations more collegial and productive.
Evolent Announces Focus on Specialty Care With Rebrand, Unification of Solutions
Company's solutions are coming together to improve outcomes for people living with complex health conditions.
It's Cancer Prevention Month. Here are 11 ways to reduce your risk.
Our CMO, Dr. Andrew Hertler, talks to Yahoo Life about identifying which patients need genetic testing or aggressive cancer screening, the issues surrounding prophylactic surgery, and more.
Trends clinical leaders, hospital execs say will shape healthcare beyond 2024
Becker's highlights our CMO's predictions on the future of health care.
Prophylactic Mastectomy for Patients With High-Risk Gene Mutations
Dr. Andrew Hertler discussed the importance of prophylactic mastectomy for individuals carrying BRCA1, BRCA2 and other deleterious mutations.
Medicare Drug Price Negotiations and Anticipated Ripple Effects
Our vice president of pharmacy explores the hard-to-predict impacts of drug price negotiations on consumers, plans and pharmaceutical companies.
Pancreatic Cancer Screening, the New Guidelines, and Barriers to Care
Our CMO speaks with Urban Health Today about who should get screened, the role of primary care physicians in identifying at-risk individuals, and more.
Genetic Testing in Cancer Care: Considerations for a Condition-Based Approach
Two Evolent experts discuss the benefits of genetic testing in oncology in American Journal of Managed Care.
Evolent facilitates response to cancer drug shortages
Evolent takes a multifaceted approach to help providers navigate shortages of cisplatin, carboplatin and other anti-cancer drugs.
The Make-or-Break Moment for Payers in Specialty Care
Our chief strategy officer speaks with Becker's about the largely untapped potential of value-based specialty care.
Designing the High-Value Oncology Practice
Oncology Care Partners CEO Erich Mounce describes how his practices are purpose-built for value.
Reducing Cancer Therapy’s Toll on the Heart
Evolent is leveraging our expertise in two key specialties to reduce cardiovascular damage related to cancer drugs.
When Less is More in Radiation Oncology
An Evolent program reduces unnecessary radiation treatments for breast cancer without compromising efficacy.
How to Talk to Family Members About Hospice and End-of-Life Care
Evolent's Connie Ducaine writes in MarketWatch that patients need to be proactive to ensure their preferences for end of life are respected.
1:34Connecting Our Businesses. Connecting Care.
Our solutions are coming together under one brand to improve outcomes for people with complex health conditions.
A 'Pink Tax' in Oncology?
Evolent addresses a startling difference in what men and women pay for the same drug.
Bending the Oncology Cost Curve in 2023 and Beyond
Our chief medical officer shares three trends likely to impact oncology drug spend in the near future.